This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Poindessous, V. Articles by Larsen, A. K. Search for Related Content PubMed PubMed Citation Articles by Poindessous, V. Articles by Larsen, A. K.

Marked Activity of Irofulven toward Human Carcinoma Cells

Comparison with Cisplatin and Ecteinascidin¹

Laboratory of Biology and Pharmacogenetics of Human Tumors, Centre National de la Recherche Scientifique Unité Mixte de Recherche, Ecole Normale Supérieure, Cachan and Institut Gustave-Roussy, Villejuif 94805 cedex, France [V. P., F. K., E. R., M. C., A. K. L]; Department of Medicine, Institut Gustave-Roussy, France [E. R.]; and Research and Development, MGI Pharma, Inc., Bloomington, MN [S. J. W.]

Purpose: To characterize the activities of irofulven, a novelanticancer agent derived from the mushroom natural productilludin S toward human cancer cells.

Experimental Design: We have determined the activity spectrum of irofulven toward a human tumor cell panel comprised of 10 different tumor types in comparison with cisplatin and ET-743. We have also evaluated the influence of major resistance mechanisms, such as expression of multidrug resistance-associated drug efflux pumps, cisplatin resistance, loss of p53 function, and absence of mismatch repair on the cytotoxic activity of irofulven.

Results: The activity spectrum of irofulven is clearly different from that of ET-743 and cisplatin. Irofulven shows excellent cytotoxicity toward the majority of human carcinoma cell lines tested, but lesser activity toward sarcoma and leukemia cell lines. The cytotoxic activity of irofulven was particularly pronounced toward head and neck, non-small cell lung, colon, and ovary carcinoma cells, as well as toward malignant glioma cell lines. In addition, irofulven displayed good activity toward poorly differentiated, androgen-independent prostate cancer cells and cell lines expressing high levels of the detoxifying enzymes glutathione S-transferase and -glutamyl cysteine synthetase. The cytotoxicity of irofulven was not affected by loss of p53 or mismatch repair function, and the drug was not a substrate for multidrug transporters, such as the P-glycoprotein and multidrug resistance protein 1.

Conclusions: Irofulven has an unusual activity spectrum with strong activity toward tumor cells of epithelial origin. Furthermore, irofulven is not or only marginally affected by resistance mechanisms limiting the efficacy of other alkylating agents.

This article has been cited by other articles:

				A. E. Escargueil, V. Poindessous, D. G. Soares, A. Sarasin, P. R. Cook, and A. K. Larsen Influence of irofulven, a transcription-coupled repair-specific antitumor agent, on RNA polymerase activity, stability and dynamics in living mammalian cells J. Cell Sci., April 15, 2008; 121(8): 1275 - 1283. [Abstract] [Full Text] [PDF]

				D. G. Soares, A. E. Escargueil, V. Poindessous, A. Sarasin, A. de Gramont, D. Bonatto, J. A. P. Henriques, and A. K. Larsen From the Cover: Replication and homologous recombination repair regulate DNA double-strand break formation by the antitumor alkylator ecteinascidin 743 PNAS, August 7, 2007; 104(32): 13062 - 13067. [Abstract] [Full Text] [PDF]

				L. Amaral, M. Martins, and M. Viveiros Enhanced killing of intracellular multidrug-resistant Mycobacterium tuberculosis by compounds that affect the activity of efflux pumps J. Antimicrob. Chemother., June 1, 2007; 59(6): 1237 - 1246. [Abstract] [Full Text] [PDF]

				A. Paci, K. Rezai, A. Deroussent, D. De Valeriola, M. Re, S. Weill, E. Cvitkovic, C. Kahatt, A. Shah, S. Waters, et al. Pharmacokinetics, Metabolism, and Routes of Excretion of Intravenous Irofulven in Patients with Advanced Solid Tumors Drug Metab. Dispos., November 1, 2006; 34(11): 1918 - 1926. [Abstract] [Full Text] [PDF]

				N. Martinez, M. Sanchez-Beato, A. Carnero, V. Moneo, J. C. Tercero, I. Fernandez, M. Navarrete, J. Jimeno, and M. A. Piris Transcriptional signature of Ecteinascidin 743 (Yondelis, Trabectedin) in human sarcoma cells explanted from chemo-naive patients Mol. Cancer Ther., May 1, 2005; 4(5): 814 - 823. [Abstract] [Full Text] [PDF]

				K. Lemke, V. Poindessous, A. Skladanowski, and A. K. Larsen The Antitumor Triazoloacridone C-1305 Is a Topoisomerase II Poison with Unusual Properties Mol. Pharmacol., October 1, 2004; 66(4): 1035 - 1042. [Abstract] [Full Text] [PDF]

				J. Wang, T. Wiltshire, Y. Wang, C. Mikell, J. Burks, C. Cunningham, E. S. Van Laar, S. J. Waters, E. Reed, and W. Wang ATM-dependent CHK2 Activation Induced by Anticancer Agent, Irofulven J. Biol. Chem., September 17, 2004; 279(38): 39584 - 39592. [Abstract] [Full Text] [PDF]

				F. Koeppel, V. Poindessous, V. Lazar, E. Raymond, A. Sarasin, and A. K. Larsen Irofulven Cytotoxicity Depends on Transcription-Coupled Nucleotide Excision Repair and Is Correlated with XPG Expression in Solid Tumor Cells Clin. Cancer Res., August 15, 2004; 10(16): 5604 - 5613. [Abstract] [Full Text] [PDF]

				J. Alexandre, E. Raymond, M. O. Kaci, E. C. Brain, F. Lokiec, C. Kahatt, S. Faivre, A. Yovine, F. Goldwasser, S. L. Smith, et al. Phase I and Pharmacokinetic Study of Irofulven Administered Weekly or Biweekly in Advanced Solid Tumor Patients Clin. Cancer Res., May 15, 2004; 10(10): 3377 - 3385. [Abstract] [Full Text] [PDF]